NCT05881993

Study of CBP-4888 in Healthy, Non-Pregnant Female Subjects

Completed EARLY_PHASE1 Last updated 26 September 2025

What this trial tests

EARLY_PHASE1 trial testing CBP-4888 in Healthy Volunteer Study in 45 participants. Completed in 22 May 2024.

Timeline

22 May 2023

Primary endpoint
22 May 2024

22 May 2024

Quick facts

Lead sponsor	Comanche Biopharma
Phase	EARLY_PHASE1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	45
Start date	22 May 2023
Primary completion	22 May 2024
Estimated completion	22 May 2024
Sites	1 location across United States

Drugs / interventions tested

• CBP-4888 — full drug profile →
• Placebo

Conditions studied

• Healthy Volunteer Study — all drugs for Healthy Volunteer Study →

Sponsor

Comanche Biopharma — full company profile →

Who can join

Adults 18 to 50, female only, with Healthy Volunteer Study. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a Phase I, first-in-human, single-center, randomized, double-blind, placebo-controlled, single ascending dose study to evaluate the safety, tolerability, and PK of ascending doses of CBP-4888.

Publications & conference data

6 peer-reviewed publications reference this trial (live from Europe PMC):

1. RNAi-based drug design: considerations and future directions.
   Tang Q, Khvorova A. · · 2024 · cited 168× · PMID 38570694 · DOI 10.1038/s41573-024-00912-9
2. New Ideas for the Prevention and Treatment of Preeclampsia and Their Molecular Inspirations.
   Sakowicz A, Bralewska M, Rybak-Krzyszkowska M, Grzesiak M, et al · · 2023 · cited 28× · PMID 37569476 · DOI 10.3390/ijms241512100
3. A programmable dual-targeting siRNA scaffold supports potent two-gene modulation in the central nervous system.
   Belgrad J, Tang Q, Hildebrand S, Summers A, et al · · 2024 · cited 20× · PMID 38726879 · DOI 10.1093/nar/gkae368
4. Implications of pregnancy on cardiometabolic disease risk: preeclampsia and gestational diabetes.
   Elgazzaz M, Woodham PC, Maher J, Faulkner JL. · · 2024 · cited 15× · PMID 39010840 · DOI 10.1152/ajpcell.00293.2024
5. A novel bispecific siRNA concept: Efficient dual knockdown of <i>YAP1</i> and <i>WWTR1</i> with a single guide strand.
   Ueda K, Yamada Y, Tanaka H, Sato T, et al · · 2025 · PMID 41341748 · DOI 10.1016/j.omtn.2025.102768
6. Phosphatidylcholine head group chemistry alters the extrahepatic accumulation of lipid-conjugated siRNA
   Hariharan V, Nakamura T, Shin M, Tang Q, et al · · 2024